1
|
Izar MC, Fonzar WT, Silva TP, Franca CN, Fonseca HAR, Teixeira D, Maugeri IML, Coste MER, Bianco HT, Pesquero JB, Rodrigues AAE, Carvalho ACC, Fonseca FAH. P5388Role of the immune-inflammatory biomarkers and atherosclerosis development in subjects with familial hypercholesterolemia. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M C Izar
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | - W T Fonzar
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | - T P Silva
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | - C N Franca
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | | | - D Teixeira
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | | | - M E R Coste
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | - H T Bianco
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | - J B Pesquero
- Federal University of Sao Paulo, Sao Paulo, Brazil
| | | | | | | |
Collapse
|
2
|
Tavares F, Caixeta A, Alves CMR, Barbosa AHP, Souza JAM, Sousa JMA, Santos GRF, Cintra GF, Carvalho AC, Fonseca FAH. P5599Prognostic role of neutrophil to lymphocyte ratio ST-elevation acute myocardial infarction undergoing pharmacoinvasive strategy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Tavares
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - A Caixeta
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - C M R Alves
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - A H P Barbosa
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - J A M Souza
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - J M A Sousa
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - G R F Santos
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - G F Cintra
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - A C Carvalho
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| | - F A H Fonseca
- Federal University of Sao Paulo (UNIFESP), Department of Cardiovascular Interventions, Sao Paulo, Brazil
| |
Collapse
|
3
|
Ferreira CES, França CN, Izar MCO, Camargo LM, Roman RM, Fonseca FAH. High-intensity statin monotherapy versus moderate-intensity statin plus ezetimibe therapy: effects on vascular biomarkers. Int J Cardiol 2014; 180:78-9. [PMID: 25438220 DOI: 10.1016/j.ijcard.2014.11.177] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2014] [Accepted: 11/23/2014] [Indexed: 01/05/2023]
Affiliation(s)
- C E S Ferreira
- Department of Medicine, Cardiology Division, Federal University of Sao Paulo, Sao Paulo, Brazil; Albert Einstein Israeli Hospital, Sao Paulo, Brazil
| | - C N França
- Department of Medicine, Cardiology Division, Federal University of Sao Paulo, Sao Paulo, Brazil
| | - M C O Izar
- Department of Medicine, Cardiology Division, Federal University of Sao Paulo, Sao Paulo, Brazil
| | - L M Camargo
- Department of Medicine, Cardiology Division, Federal University of Sao Paulo, Sao Paulo, Brazil
| | - R M Roman
- Federal University of Rio Grande do Sul, Porto Alegre, Brazil
| | - F A H Fonseca
- Department of Medicine, Cardiology Division, Federal University of Sao Paulo, Sao Paulo, Brazil.
| |
Collapse
|
4
|
Camargo LM, França CN, Izar MC, Bianco HT, Lins LS, Barbosa SP, Pinheiro LF, Fonseca FAH. Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy. ACTA ACUST UNITED AC 2014; 47:432-7. [PMID: 24760119 PMCID: PMC4075313 DOI: 10.1590/1414-431x20143628] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2013] [Accepted: 02/20/2014] [Indexed: 01/14/2023]
Abstract
It is not known whether the addition of ezetimibe to statins adds cardiovascular
protection beyond the expected changes in lipid levels. Subjects with coronary heart
disease were treated with four consecutive 1-week courses of therapy (T) and
evaluations. The courses were: T1, 100 mg aspirin alone; T2, 100 mg aspirin and 40 mg
simvastatin/10 mg ezetimibe; T3, 40 mg simvastatin/10 mg ezetimibe, and 75 mg
clopidogrel (300 mg initial loading dose); T4, 75 mg clopidogrel alone. Platelet
aggregation was examined in whole blood. Endothelial microparticles (CD51), platelet
microparticles (CD42/CD31), and endothelial progenitor cells (CD34/CD133;
CDKDR/CD133, or CD34/KDR) were quantified by flow cytometry. Endothelial function was
examined by flow-mediated dilation. Comparisons between therapies revealed
differences in lipids (T2 and T3<T1 and T4 for total cholesterol, LDL-C, and
triglycerides; P<0.002 for all), as well as for endothelial function (T2>T1 and
T4, P=0.001). Decreased platelet aggregation was observed after aspirin (arachidonic
acid, T1<T3 and T4, P=0.034) and clopidogrel (adenosine, T3 and T4<T1 and T2,
P<0.0001) therapy. Simvastatin/ezetimibe diphosphate did not change platelet
aggregation, the amount of circulating endothelial and platelet microparticles, or
endothelial progenitor cells. Cardiovascular protection following therapy with
simvastatin/ezetimibe seems restricted to lipid changes and improvement of
endothelial function not affecting the release of microparticles, mobilization of
endothelial progenitor cells or decreased platelet aggregation.
Collapse
Affiliation(s)
- L M Camargo
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - C N França
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - M C Izar
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - H T Bianco
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - L S Lins
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - S P Barbosa
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - L F Pinheiro
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| | - F A H Fonseca
- Departamento de Medicina, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|
5
|
Simão AF, Precoma DB, Andrade JP, Correa Filho H, Saraiva JFK, Oliveira GMM, Murro ALB, Campos A, Alessi A, Avezum Junior A, Miguel ACMG, Sousa ACS, Lotemberg AMP, Lins AP, Falud AA, Brandão AA, Sanjuliani AF, Sbissa AS, Santos Filho AC, Herdy AH, Polanczyk CA, Lantieri CJ, Machado CA, Scherr C, Stoll C, Amodeo C, Araújo CGS, Saraiva D, Moriguchi EH, Mesquita ET, Cesena FHY, Fonseca FAH, Campos GP, Soares GP, Feitosa GS, Xavier HT, Castro I, Giuliano ICB, Rivera IV, Guimaraes ICB, Issa JS, Souza JRM, Faria Neto JR, Cunha LBN, Pellanda LC, Bortolotto LA, Bertolami MC, Miname MH, Gomes MAM, Tambascia M, Malachias MVB, Silva MAM, Iza MCO, Magalhães MEC, Bacellar MSC, Milani M, Wajngarten M, Ghorayeb N, Coelho OR, Villela PB, Jardim PCBV, Santos Filho RD, Stein R, Cassani RSL, D'Avila RL, Ferreira RM, Barbosa RB, Povoa RMS, Kaiser SE, Ismael SC, Carvalho T, Giraldez VZR, Coutinho W, Souza WKSB. I Diretriz Brasileira de Prevenção Cardiovascular. Arq Bras Cardiol 2013; 101:1-63. [DOI: 10.5935/abc.2013s012] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Santos RD, Gagliardi ACM, Xavier HT, Magnoni CD, Cassani R, Lottenberg AMP, Casella Filho A, Araújo DB, Cesena FY, Alves RJ, Fenelon G, Nishioka SAD, Faludi AA, Geloneze B, Scherr C, Kovacs C, Tomazzela C, Carla C, Barrera-Arellano D, Cintra D, Quintão E, Nakandakare ER, Fonseca FAH, Pimentel I, Santos JE, Bertolami MC, Rogero M, Izar MCO, Nakasato M, Damasceno NRT, Maranhão R, Cassani RSL, Perim R, Ramos S. I Diretriz sobre o consumo de Gorduras e Saúde Cardiovascular. Arq Bras Cardiol 2013. [DOI: 10.5935/abc.2013s003] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Relvas WGM, Izar MCO, Helfenstein T, Ihara SSM, Pomaro DR, França CN, Lopes JD, Mariano M, Carvalho ACC, Fonseca FAH. I 003 Resident Peritoneal Inflammatory Cells are Pivotal in the Development of Experimental Atherosclerosis. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71757-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Monteiro CMC, Izar MCO, Pinheiro LFM, Oliveira L, Santos AO, Fischer SCPM, Paola AAV, Carvalho ACC, Fonseca FAH. A 005 Early Effects of Lipid Lowering Treatment in Subjects with Metabolic Syndrome and Acute Coronary Syndromes. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71668-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Monteiro CMC, Izar MCO, Pinheiro LFM, Brandão SAB, Oliveira L, Fischer SCPM, Santos AO, Paola AAV, Carvalho ACC, Fonseca FAH. A 003 Highly Sensitive C-reactive Protein and the Framingham Risk Score are Independently Related to the Severity of Coronary Disease in Patients with Metabolic Syndrome. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71666-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Henrique PJ, Helfenstein T, Fonseca FAH, Ihara SSM, Bottos JM, Farah ME, Pomaro DR, Carvalho ACC, Izar MCO. D 003 Experimental Model of Diet Induced Type 2 Diabetes and Atherosclerosis in Rabbits. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71697-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Monteiro CMC, Izar MCO, Pinheiro LFM, Brandão SAB, Oliveira L, Fischer SCPM, Santos AO, Carvalho ACC, Paola AAV, Fonseca FAH. L 002 Early Glucometabolic Profile in Patients with Acute Coronary Syndromes and Metabolic Syndrome. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71768-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Santos AO, Fonseca FAH, Fischer SCPM, Monteiro CMC, Brandão SAB, Monteiro AM, Sanches EMR, Gidlund MA, Figueiredo A, Carvalho ACC, Izar MCO. I 002 High Circulating Autoantibodies Against Human Oxidized LDL are Related to Stable and Lower Titers to Unstable Clinical Situation. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71756-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Pomaro DR, Andrade L, Fonseca FAH, Izar MCO, Pinto LESA, Casarini DE, Ihara SSM. D 006 ACE Inhibitor Protects Aorta, Lever and Kidney of Hypercholesterolemic and Diabetic Rabbits. ATHEROSCLEROSIS SUPP 2009. [DOI: 10.1016/s1567-5688(09)71700-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Fischer SCPM, Santos AO, Monteiro AM, Sanches EMR, Brandão SAB, Helfenstein T, Monteiro CMC, Gidlund MA, Izar MCO, Fonseca FAH. H 009 ACE-INHIBITORS AND DIURETICS REDUCE TITERS OF ANTIBODIES ANTI-OXLDL IN HYPERTENSIVE PATIENTS. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71912-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Santos AO, Fischer SCPM, Monteiro CMC, Monteiro AM, Sanches EMR, Helfenstein T, Brandão SAB, Gidlund MA, Fonseca FAH, Izar MCO. L 015 LOW TITERS OF HUMAN ANTIOXIDIZED LDL AUTOANTIBODIES ARE ASSOCIATED WITH UNSTABLE CORONARY DISEASE. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71959-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
16
|
Fonseca FAH, Monteiro CMC, Santos AO, Fischer SCPM, Alves SIPMN, Gidlund MA, Figueiredo A, Izar MCO. L 053 CHARACTERIZATION OF OXIDIZED LDL BY THE Z-SCAN TECHNIQUE IN PATIENTS WITH METABOLIC SYNDROME AFTER AN ACUTE CORONARY EVENT. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71997-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
17
|
Helfenstein T, Ihara SSM, Santos AO, Relvas WGM, Souza DRS, Scartezini M, Han SW, Fonseca MIH, Pinto LDESA, Fonseca FAH, Izar MCO. D 003 CAN GENETIC MARKERS PREDICT CORONARY RISK IN TYPE 2 DIABETES OVER AND ABOVE CLASSIC RISK FACTORS? ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71894-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Izar MCO, Pinto LDESA, Lopes IEL, Fischer SCPM, Fonseca MIH, Ihara SSM, Kasinski N, Fonseca FAH. L 025 APOB X LDL-C/APOA1 X HDL-C: A NEW PREDICTOR OF CORONARY RISK. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)71969-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Feio CMA, Fonseca FAH, Feio MNB, Feio TA. L 063 LIPID PROFILE AND CARDIOVASCULAR RISK IN A POPULATION FROM THE MARAJÓ ISLAND. ATHEROSCLEROSIS SUPP 2007. [DOI: 10.1016/s1567-5688(07)72007-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Middleton A, Binbrek AS, Fonseca FAH, Wilpshaar W, Watkins C, Strandberg TE. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr Med Res Opin 2006; 22:1181-91. [PMID: 16846551 DOI: 10.1185/030079906x100177] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND There is an increasing body of evidence to support the benefits of reducing low-density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of LDL-C goals recommended by international guidelines. Therefore, there is a growing need for effective lipid-modifying therapies to optimise the achievement of these more stringent LDL-C goals. OBJECTIVE A meta-analysis of data pooled from five studies participating in the DISCOVERY (DIrect Statin COmparison of LDL-C Values: an Evaluation of Rosuvastatin therapY) Programme was performed to compare the effect of rosuvastatin treatment with other statins in real-life clinical practice. RESULTS These studies included 6743 patients with hypercholesterolaemia from different ethnicities, countries and cultural environments. The meta-analysis showed that significantly more patients receiving rosuvastatin 10 mg achieved the 2003 European LDL-C goals compared with those who received atorvastatin 10 mg or simvastatin 20 mg (p < 0.001 for both comparisons). A significantly greater proportion of patients receiving rosuvastatin 10 mg also achieved the 2003 European total cholesterol goal compared with those on atorvastatin 10 mg (p < 0.001). CONCLUSIONS The meta-analysis showed that rosuvastatin was more effective than comparator statins at lowering LDL-C levels and enabling patients to achieve lipid goals at recommended start doses. In addition, all statins studied were well tolerated and confirmed that rosuvastatin had a similar safety profile to other statins.
Collapse
|
21
|
Relvas WGM, Izar MCO, Helfenstein T, Fonseca MIH, Colovati M, Oliveira A, Ihara SSM, Han SW, Las Casas AA, Fonseca FAH. Relationship between gene polymorphisms and prevalence of myocardial infarction among diabetic and non-diabetic subjects. Atherosclerosis 2005; 178:101-5. [PMID: 15585206 DOI: 10.1016/j.atherosclerosis.2004.05.025] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2003] [Revised: 05/04/2004] [Accepted: 05/25/2004] [Indexed: 10/26/2022]
Abstract
This study was aimed to examine cholesteryl ester transfer protein (CETP), apolipoprotein AI and CIII gene polymorphisms, and to verify whether these genetic determinants are associated with the prevalence of myocardial infarction (MI) or type 2 diabetes. The TaqIB restriction fragment length polymorphism (RFLP) in intron I of the CETP gene, the MspI in the third intron of the APOAI gene, and also SstI in the 3' untranslated region of the APOCIII gene were determined using standard methods. The prevalence of these polymorphisms was compared between diabetic (n = 119), and non-diabetic (n = 100) middle-aged individuals of both sexes. We found a higher prevalence of the B2B2 genotype of the CETP gene among diabetics than that observed in non-diabetics (P < 0.05), and a lower prevalence of this genotype among patients with previous MI (P < 0.02). The MspI polymorphisms of the APOAI gene showed that M1++ genotype was found mainly in diabetic patients (P < 0.04). Conversely, the SstI polymorphism of APOCIII gene was not significantly associated with either MI or diabetes. Therefore, among these genetic polymorphisms, TaqIB of CETP and MspI of apolipoprotein AI appeared to help significantly to identify diabetic individuals. In particular, the former may have an additional role in the primary prevention of coronary disease.
Collapse
Affiliation(s)
- W G M Relvas
- Lipides, Aterosclerose e Biologia Vascular, Disciplina de Cardiologia-Universidade Federal de São Paulo, UNIFESP, Rua Pedro de Toledo 458, São Paulo 04039-001, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Fonseca FAH, Ihara SSM, Izar MCO, Silva EP, Kasinski N, Lopes IEL, Pinto LESA, Paiva TB, Tufik S, de Paola AAV, Carvalho ACC. Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol 2004; 30:779-85. [PMID: 14516418 DOI: 10.1046/j.1440-1681.2003.03911.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
1. Antihypertensive treatment has been demonstrated to result in persistent reductions in morbidity and mortality due to stroke. However, the coronary risk attributable to hypertension has been only partially reversed. We hypothesized that diuretics could have unfavourable effects on atherosclerosis. 2. New Zealand rabbits were fed a 0.5% cholesterol-enriched diet for 12 weeks, followed by a 0.1% cholesterol diet for another 12 weeks. During the last 12 week period, 40 animals were randomly assigned to one of four groups: (i) group I was the control group; (ii) group II received hydrochlorothiazide (10 mg/day); (iii) group III received quinapril (30 mg/day); and (iv) group IV was treated with hydrochlorothiazide (10 mg/day) plus quinapril (30 mg/day). 3. The treatments did not affect either the lipid profile or serum electrolytes and oxidative stress. However, endothelium-dependent vasorelaxation in isolated aortic rings was significantly improved with quinapril (group III) treatment (P < 0.001 vs other groups). In addition, therapy with quinapril promoted a significant reduction in atherosclerosis (intima area, intima/media ratio and perimeter of vessel with plaque; P < 0.05 vs other groups), as well as in cholesterol content of the aorta (P < 0.05 vs groups II and IV). 4. In conclusion, hydrochlorothiazide did not modify atherosclerosis and, when added to quinapril treatment, impaired the anti-atherosclerotic effect seen with quinapril alone.
Collapse
Affiliation(s)
- F A H Fonseca
- Division of Cardiology, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|